Recent changes at the US Food and Drug Administration (FDA) have changed the circumstances for rare disease drug development, but this remains an area of opportunity for biotechs. At the recent 3rd ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback